Home LiteratureArticle Details
PMID: 19693097 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

When mutants gain new powers: news from the mutant p53 field.

Nature reviews. Cancer ·Vol. 9 ·No. 10 ·2009-10-00 ·Pages 701-13

Brosh R, Rotter V

Abstract

Ample data indicate that mutant p53 proteins not only lose their tumour suppressive functions, but also gain new abilities that promote tumorigenesis. Moreover, recent studies have modified our view of mutant p53 proteins, portraying them not as inert mutants, but rather as regulated proteins that influence the cancer cell transcriptome and phenotype. This influence is clinically manifested as association of TP53 mutations with poor prognosis and drug resistance in a growing array of malignancies. Here, we review recent studies on mutant p53 regulation, gain-of-function mechanisms, transcriptional effects and prognostic association, with a focus on the clinical implications of these findings.

MeSH Terms
Animals Disease Models, Animal Genes, p53/genetics Humans Mice Mutation Neoplasms/metabolism Prognosis Transcription, Genetic/genetics Tumor Suppressor Protein p53/genetics
Chemicals
Tumor Suppressor Protein p53
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Brosh Ran
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel.
Rotter Varda
References (187)
187 references, click to expand
  1. Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins.
    Cancer Res. 1991 Oct 1;51(19):5232-7 PMID: 1717142
  2. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding.
    Oncogene. 1997 Sep 4;15(10):1179-89 PMID: 9294611
  3. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.
    Science. 1990 Nov 30;250(4985):1233-8 PMID: 1978757
  4. Modulation of gene expression in U251 glioblastoma cells by binding of mutant p53 R273H to intronic and intergenic sequences.
    Nucleic Acids Res. 2009 Apr;37(5):1486-500 PMID: 19139068
  5. A high prevalence of p53 mutations in pre-malignant oral erythroplakia.
    Int J Cancer. 1999 Jan 29;80(3):345-8 PMID: 9935172
  6. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain.
    Mol Cell Biol. 2001 Mar;21(5):1874-87 PMID: 11238924
  7. Growth regulation of a cellular tumour antigen, p53, in nontransformed cells.
    Nature. 1984 Mar 8-14;308(5955):199-201 PMID: 6366574
  8. Structure-function-rescue: the diverse nature of common p53 cancer mutants.
    Oncogene. 2007 Apr 2;26(15):2226-42 PMID: 17401432
  9. Prognostic implications of circulating anti-p53 antibodies in lung cancer--a review.
    Eur J Cancer Care (Engl). 2009 May;18(3):248-54 PMID: 19432918
  10. Tumor suppressor p53: analysis of wild-type and mutant p53 complexes.
    Mol Cell Biol. 1991 Jan;11(1):12-9 PMID: 1986215
  11. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome.
    J Natl Cancer Inst. 1969 Dec;43(6):1365-73 PMID: 5396222
  12. p63 and p73 in human cancer: defining the network.
    Oncogene. 2007 Aug 9;26(36):5169-83 PMID: 17334395
  13. Ubiquitination and degradation of mutant p53.
    Mol Cell Biol. 2007 Dec;27(23):8284-95 PMID: 17908790
  14. Transcriptional activities of mutant p53: when mutations are more than a loss.
    J Cell Biochem. 2004 Nov 15;93(5):878-86 PMID: 15449312
  15. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression.
    Oncogene. 2006 Jan 12;25(2):304-9 PMID: 16170357
  16. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.
    Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13550-5 PMID: 16141321
  17. Transcriptional control of the proliferation cluster by the tumor suppressor p53.
    Mol Biosyst. 2010 Jan;6(1):17-29 PMID: 20024063
  18. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    J Mol Biol. 2009 Jan 9;385(1):249-65 PMID: 18996393
  19. Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells.
    Cancer Res. 2006 Jun 15;66(12):6319-26 PMID: 16778209
  20. Breast-cancer stromal cells with TP53 mutations.
    N Engl J Med. 2008 Apr 10;358(15):1635; author reply 1636 PMID: 18411430
  21. Breast-cancer stromal cells with TP53 mutations and nodal metastases.
    N Engl J Med. 2007 Dec 20;357(25):2543-51 PMID: 18094375
  22. Increased concentration of an apparently identical cellular protein in cells transformed by either Abelson murine leukemia virus or other transforming agents.
    J Virol. 1981 Apr;38(1):336-46 PMID: 6264107
  23. Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma.
    Oncogene. 2000 Aug 3;19(33):3717-26 PMID: 10949925
  24. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells.
    Nature. 1984 Dec 13-19;312(5995):646-9 PMID: 6095116
  25. Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene.
    Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5503-8 PMID: 11960007
  26. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
    J Natl Cancer Inst. 2006 Jul 5;98(13):911-9 PMID: 16818855
  27. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.
    Oncogene. 1998 Sep 3;17(9):1061-8 PMID: 9764816
  28. MicroRNAs and cancer: short RNAs go a long way.
    Cell. 2009 Feb 20;136(4):586-91 PMID: 19239879
  29. Transcription regulation by mutant p53.
    Oncogene. 2007 Apr 2;26(15):2202-11 PMID: 17401429
  30. Evaluation of arrayed primer extension for TP53 mutation detection in breast and ovarian carcinomas.
    Biotechniques. 2005 Nov;39(5):755-61 PMID: 16312222
  31. Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival.
    Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7952-7 PMID: 11438741
  32. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma.
    Blood. 2007 Dec 15;110(13):4396-405 PMID: 17881637
  33. Detecting colorectal cancer in stool with the use of multiple genetic targets.
    J Natl Cancer Inst. 2001 Jun 6;93(11):858-65 PMID: 11390535
  34. Elevated expression of ribosomal protein genes L37, RPP-1, and S2 in the presence of mutant p53.
    Cancer Epidemiol Biomarkers Prev. 1999 Nov;8(11):1011-6 PMID: 10566557
  35. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells.
    Mol Cell Biol. 1999 Feb;19(2):1438-49 PMID: 9891077
  36. Transactivation of the EGR1 gene contributes to mutant p53 gain of function.
    Cancer Res. 2004 Nov 15;64(22):8318-27 PMID: 15548700
  37. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells.
    Cell. 1979 May;17(1):43-52 PMID: 222475
  38. TP53 gene mutations as an independent marker for urinary bladder cancer progression.
    Int J Mol Med. 2008 May;21(5):655-61 PMID: 18425359
  39. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse.
    Proc Natl Acad Sci U S A. 1979 May;76(5):2420-4 PMID: 221923
  40. Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells.
    Oncogene. 2008 Apr 10;27(17):2445-55 PMID: 17982489
  41. PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.
    Cancer Res. 2008 Mar 15;68(6):1723-31 PMID: 18339852
  42. p53 Antibodies in the sera of patients with various types of cancer: a review.
    Cancer Res. 2000 Apr 1;60(7):1777-88 PMID: 10766157
  43. Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes.
    Oncogene. 2004 May 27;23(25):4430-43 PMID: 15077194
  44. Heat shock protein 84 forms a complex with mutant p53 protein predominantly within a cytoplasmic compartment of the cell.
    J Biol Chem. 1996 Jun 21;271(25):15084-90 PMID: 8663025
  45. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients.
    Nat Med. 1996 Jul;2(7):811-4 PMID: 8673929
  46. Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction.
    Cancer Res. 2006 Nov 15;66(22):10750-9 PMID: 17108111
  47. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.
    Oncogene. 1991 Sep;6(9):1699-703 PMID: 1923535
  48. Abelson murine leukemia virus-induced tumors elicit antibodies against a host cell protein, P50.
    J Virol. 1980 Nov;36(2):547-55 PMID: 6159484
  49. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53.
    Nature. 1995 Nov 9;378(6553):203-6 PMID: 7477326
  50. Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II.
    Mol Cell Biol. 2007 Dec;27(23):8228-42 PMID: 17875924
  51. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families.
    J Med Genet. 2008 Aug;45(8):535-8 PMID: 18511570
  52. Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene.
    Cell. 1984 Aug;38(1):119-26 PMID: 6088057
  53. Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.
    EMBO J. 2001 Aug 1;20(15):4163-72 PMID: 11483519
  54. Hsp90: a novel target for cancer therapy.
    Curr Top Med Chem. 2006;6(11):1205-14 PMID: 16842157
  55. Targeting p53 for enhanced radio- and chemo-sensitivity.
    Apoptosis. 2009 Apr;14(4):597-606 PMID: 19259822
  56. T antigen is bound to a host protein in SV40-transformed cells.
    Nature. 1979 Mar 15;278(5701):261-3 PMID: 218111
  57. Oncogenomic Approaches in Exploring Gain of Function of Mutant p53.
    Curr Genomics. 2008 May;9(3):200-7 PMID: 19440517
  58. TP53 and ovarian cancer.
    Hum Mutat. 2003 Mar;21(3):285-91 PMID: 12619114
  59. TP53 in hematological cancer: low incidence of mutations with significant clinical relevance.
    Hum Mutat. 2003 Mar;21(3):277-84 PMID: 12619113
  60. Prognostic significance of p53 gene mutations and protein overexpression in localized gastrointestinal stromal tumours.
    Histopathology. 2007 Sep;51(3):379-89 PMID: 17727479
  61. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90.
    Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8379-83 PMID: 8710879
  62. Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum.
    J Virol. 1979 Aug;31(2):472-83 PMID: 225566
  63. Family feud in chemosensitvity: p73 and mutant p53.
    Cell Cycle. 2004 Mar;3(3):319-23 PMID: 14739781
  64. Molecular basis for heterogeneity of the human p53 protein.
    Mol Cell Biol. 1986 Dec;6(12):4650-6 PMID: 3025664
  65. A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma.
    Cancer Res. 2007 Nov 1;67(21):10148-58 PMID: 17981789
  66. Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas.
    J Pathol. 2009 May;218(1):66-75 PMID: 19199318
  67. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.
    Nature. 1995 Nov 9;378(6553):206-8 PMID: 7477327
  68. The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs.
    Cell Cycle. 2008 Nov 1;7(21):3440-7 PMID: 18948736
  69. The consensus coding sequences of human breast and colorectal cancers.
    Science. 2006 Oct 13;314(5797):268-74 PMID: 16959974
  70. Aflatoxin B1 induces the transversion of G-->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes.
    Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8586-90 PMID: 8397412
  71. Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants.
    Oncogene. 1995 Jun 15;10(12):2387-90 PMID: 7784087
  72. Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: a long-term study.
    Urol Oncol. 2008 Nov-Dec;26(6):620-6 PMID: 18367096
  73. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy.
    Oncogene. 1999 Jan 14;18(2):477-85 PMID: 9927204
  74. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family.
    Cancer Cell. 2005 Apr;7(4):363-73 PMID: 15837625
  75. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent.
    Mol Cell Biol. 1998 Mar;18(3):1517-24 PMID: 9488468
  76. Mutant p53 protein expression interferes with p53-independent apoptotic pathways.
    Oncogene. 1998 Jun 25;16(25):3269-77 PMID: 9681825
  77. Mutant p53 proteins bind DNA in a DNA structure-selective mode.
    Nucleic Acids Res. 2005 Feb 18;33(3):1087-100 PMID: 15722483
  78. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
    Clin Cancer Res. 2006 Feb 15;12(4):1157-67 PMID: 16489069
  79. The versatile interactions of p53 with DNA: when flexibility serves specificity.
    Cell Death Differ. 2006 Jun;13(6):885-9 PMID: 16543936
  80. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation.
    Cell. 1991 May 31;65(5):765-74 PMID: 2040013
  81. Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival.
    Clin Cancer Res. 2008 Jan 1;14(1):89-96 PMID: 18172257
  82. PTEN and p53: who will get the upper hand?
    Cancer Cell. 2003 Feb;3(2):97-9 PMID: 12620402
  83. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis.
    Cancer Cell. 2003 Apr;3(4):387-402 PMID: 12726864
  84. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array.
    Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7382-7 PMID: 10377423
  85. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation.
    Nature. 1984 Dec 13-19;312(5995):649-51 PMID: 6390217
  86. Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy.
    Cell Cycle. 2008 Jun 15;7(12):1870-9 PMID: 18594199
  87. Age-dependent prognostic effects of genetic alterations in glioblastoma.
    Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):228-33 PMID: 14734474
  88. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.
    Nature. 2003 Sep 25;425(6956):407-10 PMID: 14508491
  89. P53 transformation-related protein accumulates in the nucleus of transformed fibroblasts in association with the chromatin and is found in the cytoplasm of non-transformed fibroblasts.
    EMBO J. 1983;2(7):1041-7 PMID: 6354706
  90. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway.
    Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6302-7 PMID: 18424558
  91. Detection of K-ras and p53 gene mutations in pancreatic juice for the diagnosis of intraductal papillary mucinous tumors.
    Pancreas. 2001 Jan;22(1):108-9 PMID: 11138964
  92. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53.
    Science. 1992 Jan 24;255(5043):459-62 PMID: 1346476
  93. Transcriptional functionality of germ line p53 mutants influences cancer phenotype.
    Clin Cancer Res. 2007 Jul 1;13(13):3789-95 PMID: 17606709
  94. The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation.
    Mol Syst Biol. 2005;1:2005.0022 PMID: 16729057
  95. p53 alterations in human cancer: more questions than answers.
    Oncogene. 2007 Apr 2;26(15):2145-56 PMID: 17401423
  96. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype.
    Leukemia. 2009 Jan;23(1):117-24 PMID: 18843282
  97. Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations.
    Cancer Res. 2008 Aug 15;68(16):6789-96 PMID: 18701504
  98. Regulation of p53 nuclear export through sequential changes in conformation and ubiquitination.
    J Biol Chem. 2007 May 11;282(19):14616-25 PMID: 17371868
  99. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?
    Oncogene. 2007 Apr 2;26(15):2220-5 PMID: 17401431
  100. Decision making by p53: life, death and cancer.
    Cell Death Differ. 2003 Apr;10(4):431-42 PMID: 12719720
  101. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis.
    Mol Cell Biol. 1990 Dec;10(12):6565-77 PMID: 2247074
  102. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma.
    Clin Cancer Res. 2005 Jan 1;11(1):232-41 PMID: 15671551
  103. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells.
    J Virol. 1992 Oct;66(10):6164-70 PMID: 1356162
  104. TP53 mutations are associated with a particular pattern of genomic imbalances in breast carcinomas.
    J Pathol. 2005 Sep;207(1):14-9 PMID: 16007576
  105. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
    Cancer Res. 2000 Dec 15;60(24):6788-93 PMID: 11156366
  106. Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers.
    Carcinogenesis. 2007 Feb;28(2):289-98 PMID: 16861262
  107. Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil.
    Oncogene. 2002 Jul 11;21(30):4595-600 PMID: 12096336
  108. Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants.
    Oncogene. 2003 Aug 28;22(36):5667-76 PMID: 12944915
  109. Modulation of gene expression by tumor-derived p53 mutants.
    Cancer Res. 2004 Oct 15;64(20):7447-54 PMID: 15492269
  110. Mutant p53 protein in serum could be used as a molecular marker in human breast cancer.
    Int J Oncol. 2006 Apr;28(4):995-1002 PMID: 16525651
  111. Breast-cancer stromal cells with TP53 mutations.
    N Engl J Med. 2008 Apr 10;358(15):1634-5; author reply 1636 PMID: 18403774
  112. Identification of GRO1 as a critical determinant for mutant p53 gain of function.
    J Biol Chem. 2009 May 1;284(18):12178-87 PMID: 19258312
  113. TP53 mutations and codon 72 genotype--impact on survival among ovarian cancer patients.
    Ann Oncol. 2007 May;18(5):964-6 PMID: 17488735
  114. Recent advances in p53 research: an interdisciplinary perspective.
    Cancer Gene Ther. 2009 Jan;16(1):1-12 PMID: 18802452
  115. Tumor-derived p53 mutants induce NF-kappaB2 gene expression.
    Mol Cell Biol. 2005 Nov;25(22):10097-110 PMID: 16260623
  116. Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines.
    Mol Cell Biol. 1987 Aug;7(8):2863-9 PMID: 3313006
  117. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.
    Hum Mutat. 2007 Jun;28(6):622-9 PMID: 17311302
  118. A low incidence of p53 mutations in pre-malignant lesions of the oral cavity from non-tobacco users.
    Int J Cancer. 1995 Feb 8;60(4):458-63 PMID: 7829258
  119. TP53 mutations and survival in squamous-cell carcinoma of the head and neck.
    N Engl J Med. 2007 Dec 20;357(25):2552-61 PMID: 18094376
  120. Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain.
    Mol Cell Biol. 1998 Jul;18(7):3735-43 PMID: 9632756
  121. The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer.
    J Clin Oncol. 2004 Jan 1;22(1):86-96 PMID: 14701769
  122. Chaperone-dependent stabilization and degradation of p53 mutants.
    Oncogene. 2008 May 29;27(24):3371-83 PMID: 18223694
  123. Effects of mutant p53 expression on human 15-lipoxygenase-promoter activity and murine 12/15-lipoxygenase gene expression: evidence that 15-lipoxygenase is a mutator gene.
    Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4378-83 PMID: 10200270
  124. Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells.
    Prostate. 2005 Dec 1;65(4):375-89 PMID: 16037992
  125. Cloning and characterization of the human BAG-1 gene promoter: upregulation by tumor-derived p53 mutants.
    Oncogene. 1999 Aug 12;18(32):4546-53 PMID: 10467399
  126. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.
    Cell. 2004 Dec 17;119(6):847-60 PMID: 15607980
  127. Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis.
    Br J Cancer. 2006 Dec 4;95(11):1455-8 PMID: 17088904
  128. Promyelocytic leukemia protein is required for gain of function by mutant p53.
    Cancer Res. 2009 Jun 1;69(11):4818-26 PMID: 19487292
  129. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation.
    Cancer Cell. 2006 Sep;10(3):191-202 PMID: 16959611
  130. Gain of function mutations in p53.
    Nat Genet. 1993 May;4(1):42-6 PMID: 8099841
  131. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.
    Breast Cancer Res. 2007;9(3):R30 PMID: 17504517
  132. The predictive value of p53 and p33(ING1b) in patients with Dukes'C colorectal cancer.
    Colorectal Dis. 2008 May;10(4):344-51 PMID: 17949449
  133. Expression of mitotic spindle checkpoint protein hsMAD1 correlates with cellular proliferation and is activated by a gain-of-function p53 mutant.
    Cancer Res. 2002 May 1;62(9):2618-24 PMID: 11980658
  134. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas.
    Nat Genet. 2002 Nov;32(3):355-7 PMID: 12379854
  135. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.
    Oncogene. 2007 Apr 2;26(15):2157-65 PMID: 17401424
  136. TP53 mutation in colorectal cancer.
    Hum Mutat. 2003 Mar;21(3):271-6 PMID: 12619112
  137. Gain of oncogenic function of p53 mutants induces invasive phenotypes in human breast cancer cells by silencing CCN5/WISP-2.
    Cancer Res. 2008 Jun 15;68(12):4580-7 PMID: 18559502
  138. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
    Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 PMID: 11553815
  139. Mutant p53 protein localized in the cytoplasm inhibits autophagy.
    Cell Cycle. 2008 Oct;7(19):3056-61 PMID: 18818522
  140. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
    Acta Oncol. 2008;47(4):600-7 PMID: 18465328
  141. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53.
    Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3964-9 PMID: 19225112
  142. Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53.
    Nucleic Acids Res. 2007;35(6):2093-104 PMID: 17344317
  143. The C-terminus of mutant p53 is necessary for its ability to interfere with growth arrest or apoptosis.
    Oncogene. 2001 Aug 9;20(35):4891-8 PMID: 11521201
  144. p53 polymorphisms: cancer implications.
    Nat Rev Cancer. 2009 Feb;9(2):95-107 PMID: 19165225
  145. Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells.
    Cancer Res. 2007 Mar 15;67(6):2396-401 PMID: 17363555
  146. p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast.
    J Natl Cancer Inst. 2001 May 2;93(9):700-4 PMID: 11333292
  147. Gene expression patterns associated with p53 status in breast cancer.
    BMC Cancer. 2006 Dec 06;6:276 PMID: 17150101
  148. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
    Int J Oncol. 2005 Jan;26(1):65-75 PMID: 15586226
  149. p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells.
    Proc Natl Acad Sci U S A. 1983 May;80(9):2613-7 PMID: 6189126
  150. Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer.
    Int J Cancer. 2005 Sep 10;116(4):514-9 PMID: 15825182
  151. p53 hot-spot mutants increase tumor vascularization via ROS-mediated activation of the HIF1/VEGF-A pathway.
    Cancer Lett. 2009 Apr 18;276(2):143-51 PMID: 19091459
  152. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.
    Nat Cell Biol. 2007 May;9(5):573-80 PMID: 17417627
  153. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss.
    Genes Dev. 2008 May 15;22(10):1337-44 PMID: 18483220
  154. Tumor-derived p53 mutant C174Y is a gain-of-function mutant which activates the fos promoter and enhances colony formation.
    Int J Cancer. 2000 Oct 15;88(2):162-71 PMID: 11004663
  155. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.
    Cell. 2004 Dec 17;119(6):861-72 PMID: 15607981
  156. Identification of genomic DNA sequences bound by mutant p53 protein (Gly245-->Ser) in vivo.
    Oncogene. 2000 Aug 24;19(36):4178-83 PMID: 10962580
  157. Relationship between genetic alterations and prognosis in sporadic colorectal cancer.
    Int J Cancer. 2006 Apr 1;118(7):1721-7 PMID: 16231316
  158. p53 mutations in human cancers.
    Science. 1991 Jul 5;253(5015):49-53 PMID: 1905840
  159. Cancer chemoresistance: the relationship between p53 and multidrug transporters.
    Int J Cancer. 2002 Mar 20;98(3):323-30 PMID: 11920581
  160. Common markers of proliferation.
    Nat Rev Cancer. 2006 Feb;6(2):99-106 PMID: 16491069
  161. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration.
    Am J Clin Pathol. 2009 Feb;131(2):257-63 PMID: 19141386
  162. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?
    Ann Intern Med. 1969 Oct;71(4):747-52 PMID: 5360287
  163. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy.
    Nat Med. 1995 Oct;1(10):1029-34 PMID: 7489358
  164. mdm2 expression is induced by wild type p53 activity.
    EMBO J. 1993 Feb;12(2):461-8 PMID: 8440237
  165. Assessing TP53 status in human tumours to evaluate clinical outcome.
    Nat Rev Cancer. 2001 Dec;1(3):233-40 PMID: 11902578
  166. Germline TP53 mutations and Li-Fraumeni syndrome.
    Hum Mutat. 2003 Mar;21(3):313-20 PMID: 12619118
  167. Genomic and proteomic profiles reveal the association of gelsolin to TP53 status and bladder cancer progression.
    Am J Pathol. 2007 Nov;171(5):1650-8 PMID: 17982131
  168. p16INK4a modulates p53 in primary human mammary epithelial cells.
    Cancer Res. 2006 Nov 1;66(21):10325-31 PMID: 17079452
  169. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene.
    Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8318-23 PMID: 8710868
  170. Gene-expression signatures in breast cancer.
    N Engl J Med. 2009 Feb 19;360(8):790-800 PMID: 19228622
  171. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.
    Blood. 2008 Oct 15;112(8):3088-98 PMID: 18559976
  172. Analysis of p53 mutations in cells taken from paraffin-embedded tissue sections of ductal carcinoma in situ and atypical ductal hyperplasia of the breast.
    Cancer Lett. 2004 Aug 20;212(1):121-30 PMID: 15246568
  173. Mdm2 promotes the rapid degradation of p53.
    Nature. 1997 May 15;387(6630):296-9 PMID: 9153395
  174. Surfing the p53 network.
    Nature. 2000 Nov 16;408(6810):307-10 PMID: 11099028
  175. p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation.
    Mol Syst Biol. 2008;4:229 PMID: 19034270
  176. Utilization of genomic signatures to direct use of primary chemotherapy.
    Curr Opin Genet Dev. 2008 Feb;18(1):62-7 PMID: 18339540
  177. Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters.
    Mol Cell Biol. 2005 May;25(9):3737-51 PMID: 15831478
  178. Rescuing the function of mutant p53.
    Nat Rev Cancer. 2001 Oct;1(1):68-76 PMID: 11900253
  179. TP53 and head and neck neoplasms.
    Hum Mutat. 2003 Mar;21(3):252-7 PMID: 12619110
  180. Increased expression of mutant forms of p53 oncogene in primary lung cancer.
    Lancet. 1990 Mar 24;335(8691):675-9 PMID: 1969059
  181. Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection.
    Carcinogenesis. 2007 Jun;28(6):1241-6 PMID: 17259658
  182. Control of autophagy by oncogenes and tumor suppressor genes.
    Cell Death Differ. 2009 Jan;16(1):87-93 PMID: 18806760
  183. The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation.
    J Biol Chem. 2005 Jul 22;280(29):27443-8 PMID: 15911628
  184. Mutant p53: an oncogenic transcription factor.
    Oncogene. 2007 Apr 2;26(15):2212-9 PMID: 17401430
  185. Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53.
    Oncogene. 2006 Jan 19;25(3):359-69 PMID: 16170349
  186. Restoration of p53 to limit tumor growth.
    Curr Opin Oncol. 2008 Jan;20(1):90-6 PMID: 18043262
  187. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.
    Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8424-9 PMID: 12826609
Article Info
Journal
Nature reviews. Cancer
Abbr.
Nat Rev Cancer
ISSN
1474-1768
DOI
10.1038/nrc2693
Published
2009-10-00
Epub
2009-00-20
Pages
701-13
Language
English
Region
England
NLM ID
101124168
Subset
IM
External Links
PubMed source DOI: 10.1038/nrc2693 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2